<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639193</url>
  </required_header>
  <id_info>
    <org_study_id>191990</org_study_id>
    <nct_id>NCT04639193</nct_id>
  </id_info>
  <brief_title>Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea</brief_title>
  <acronym>RESCUE-Combo</acronym>
  <official_title>Rescuing OSA Patients Unable to Tolerate CPAP Using Endotype-Targeted Combination Drug Therapy: a Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is common and associated with many adverse health consequences,&#xD;
      but many patients are unable to tolerate standard therapies such as continuous positive&#xD;
      airway pressure (CPAP) and thus remain untreated. Single-drug therapies have shown promising&#xD;
      results in treating sleep apnea, but on average patients have only experienced partial&#xD;
      relief. Multi-drug therapy may offer a more effective treatment approach. The goal of this&#xD;
      study is to test the effect of combination therapy with three FDA-approved drugs (Diamox&#xD;
      [acetazolamide], Lunesta [eszopiclone] +/- Effexor [venlafaxine]) on OSA severity and&#xD;
      physiology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will undergo three 3-day drug regimens. On days 1 and 2 of each drug&#xD;
      regimen, subjects will take the study drugs at home; on day 3 of each drug regimen subjects&#xD;
      will take the study drugs as part of an overnight inlab sleep study (including assessments of&#xD;
      sleepiness/alertness, sleep quality and blood pressure). Initially subjects will take&#xD;
      dual-therapy (acetazolamide+eszopiclone) vs placebo in random order; if sleep apnea resolved&#xD;
      with dual-therapy, then subjects will undergo an open-label single-drug regimen&#xD;
      (acetazolamide), else an open-label triple-drug regimen (acetazolamide + eszopiclone +&#xD;
      venlafaxine).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, cross-over trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea Hypopnea Index (AHI) during supine Non-Rapid Eye Movement (NREM) sleep</measure>
    <time_frame>3 nights</time_frame>
    <description>The AHI is a measure of sleep apnea severity and is defined as the number of apneas (no breathing for 10+ seconds) and hypopneas (reduced breathing for 10+ seconds associated with a &gt;=3% desaturation or cortical arousal) per hour of sleep. To avoid confounding by sleep stages and positions across study nights we will focus on the AHI during supine NREM sleep.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SpO2 Nadir</measure>
    <time_frame>3 nights</time_frame>
    <description>The lowest measured blood oxygen saturation during the overnight sleep study measured in percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathophysiological Traits</measure>
    <time_frame>3 nights</time_frame>
    <description>Changes in pathophysiological traits (Vpassive, Vactive, Arousal Threshold, Loop Gain) will be quantified as %Veupnea from polysomnography data using a validated algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders</measure>
    <time_frame>3 nights</time_frame>
    <description>Responders will be defined as a drop in AHI&gt;50% to &lt;10/h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Sleepiness: Stanford Sleepiness Scale (SSS)</measure>
    <time_frame>3 nights</time_frame>
    <description>Subjective sleepiness will be assessed using the Stanford Sleepiness Scale (SSS) in the morning following the overnight sleep study. The score ranges from 1 to 7, with greater values indicating more sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vigilance</measure>
    <time_frame>3 nights</time_frame>
    <description>Vigilance will be assessed using the 5-minute psychomotor vigilance test (PVT) in the morning following the overnight sleep study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep Disturbance</measure>
    <time_frame>3 nights</time_frame>
    <description>Sleep quality will be assessed based on a modified 8-question PROMIS Sleep Disturbance questionnaire in the morning following the overnight sleep study. The raw score ranges from 8 to 40 and is translated into a T-score, a standardized score with a mean of 50 and a standard deviation of 10. Greater T-scores indicate greater sleep disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>3 nights</time_frame>
    <description>Systolic/Diastolic Blood Pressure (measured at rest in the morning following the overnight sleep study).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>OSA</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Placebo, then Dual-Therapy, then Single/Triple-Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will start with a 3-day PLACEBO regimen:&#xD;
Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.&#xD;
Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.&#xD;
Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.&#xD;
After a wash-out period of 4+ days, subjects will then cross-over to a 3-day EXPERIMENTAL DUAL-regimen:&#xD;
Day 1: Acetazolamide 250mg at bedtime at home.&#xD;
Day 2: Acetazolamide 500mg at bedtime at home.&#xD;
Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.&#xD;
After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:&#xD;
Day 1: Acetazolamide 250mg at bedtime at home.&#xD;
Day 2: Acetazolamide 500mg at bedtime at home.&#xD;
Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual-Therapy, then Placebo, then Single/Triple-Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will start with a 3-day EXPERIMENTAL DUAL-regimen:&#xD;
Day 1: Acetazolamide 250mg at bedtime at home.&#xD;
Day 2: Acetazolamide 500mg at bedtime at home.&#xD;
Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.&#xD;
After a wash-out period of 4+ days, subjects will then cross-over to a 3-day PLACEBO regimen:&#xD;
Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.&#xD;
Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.&#xD;
Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.&#xD;
After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:&#xD;
Day 1: Acetazolamide 250mg at bedtime at home.&#xD;
Day 2: Acetazolamide 500mg at bedtime at home.&#xD;
Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Acetazolamide tablet (encapsulated)</description>
    <arm_group_label>Dual-Therapy, then Placebo, then Single/Triple-Therapy</arm_group_label>
    <arm_group_label>Placebo, then Dual-Therapy, then Single/Triple-Therapy</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>Eszopiclone tablet (encapsulated)</description>
    <arm_group_label>Dual-Therapy, then Placebo, then Single/Triple-Therapy</arm_group_label>
    <arm_group_label>Placebo, then Dual-Therapy, then Single/Triple-Therapy</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone</description>
    <arm_group_label>Dual-Therapy, then Placebo, then Single/Triple-Therapy</arm_group_label>
    <arm_group_label>Placebo, then Dual-Therapy, then Single/Triple-Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Venlafaxine capsule</description>
    <arm_group_label>Dual-Therapy, then Placebo, then Single/Triple-Therapy</arm_group_label>
    <arm_group_label>Placebo, then Dual-Therapy, then Single/Triple-Therapy</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18-40 kg/m2&#xD;
&#xD;
          -  Untreated Moderate or Severe OSA (AHI during supine NREM sleep &gt;15/h) with a fraction&#xD;
             of hypopneas &gt;25% of all events&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Adherent with effective therapy for OSA&#xD;
&#xD;
          -  Other known untreated sleep fragmenting disorder, such as periodic limb movement&#xD;
             disorder, or narcolepsy&#xD;
&#xD;
          -  Inability to sleep supine for overnight sleep studies&#xD;
&#xD;
          -  Circadian rhythm disorder&#xD;
&#xD;
          -  Unrevascularized coronary artery disease, angina, prior heart attack or stroke,&#xD;
             congestive heart failure&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt;160mmHg, diastolic blood pressure&#xD;
             &gt;95mmHg)&#xD;
&#xD;
          -  Presence of tracheostomy&#xD;
&#xD;
          -  Hospitalization within the past 90 days&#xD;
&#xD;
          -  Prior peptic ulcer disease, esophageal varices, or gastrointestinal bleeding (&lt; 5&#xD;
             years)&#xD;
&#xD;
          -  Prior gastric bypass surgery&#xD;
&#xD;
          -  Chronic liver disease or end-stage kidney disease&#xD;
&#xD;
          -  Active illicit substance use or &gt;2 oz daily alcohol use (i.e. &gt;2 12 oz bottles of&#xD;
             beers, &gt;2 5 oz glasses of wine, &gt;2 1.5 oz glasses of hard liquor such as spirits, gin,&#xD;
             whiskey, etc.)&#xD;
&#xD;
          -  Psychiatric disease, other than well controlled depression/anxiety&#xD;
&#xD;
          -  Cognitive impairment, inability to provide consent, or inability to complete research&#xD;
             procedures (e.g. questionnaires that are only available/validated in English)&#xD;
&#xD;
          -  Chronically using study drugs or drugs with similar pharmacodynamic effects&#xD;
             (acetazolamide - carbonic anhydrase inhibitors, eszopiclone - benzodiazepine receptor&#xD;
             agonists, venlafaxine - serotonin/norepinephrine reuptake inhibitors and other&#xD;
             antidepressants)&#xD;
&#xD;
          -  Regular use of medications known to affect control of breathing (opioids,&#xD;
             benzodiazepines, theophylline)&#xD;
&#xD;
          -  Contraindications to taking study drugs, including allergies to any of the drugs or&#xD;
             sulfa allergy; concomitant use of antidepressants, opioids, sedatives/hypnotics,&#xD;
             thiazide diuretics or angiotensin-receptor blockers; or severe nocturnal hypoxia (SpO2&#xD;
             nadir &lt;70% on diagnostic sleep study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Schmickl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Physician and Postdoctoral Fellow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela DeYoung, RPSGT</last_name>
    <phone>8582462183</phone>
    <email>pdeyoung@health.ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Institute Building</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela DeYoung, RPSGT</last_name>
      <phone>858-246-2183</phone>
      <email>pdeyoung@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dillon Gilbertson, MS</last_name>
      <phone>8582462155</phone>
      <email>dcgilbertson@health.ucsd.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCSD Health - Pulmonary and Sleep Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela DeYoung, RPSGT</last_name>
      <phone>858-246-2183</phone>
      <email>pdeyoung@health.ucsd.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Christopher Schmickl</investigator_full_name>
    <investigator_title>Associate Physician &amp; T32 Postdoctoral Fellow</investigator_title>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Eszopiclone</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

